Cargando…
Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy
OBJECTIVE: To evaluate the clinical efficacy and safety of leflunomide (LEF) combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy (PMN) and changes in anti-PLA2R antibody titers after treatment. METHODS: Sixty patients with nephrotic syndrome, biopsy-proven M...
Autores principales: | Guo, Yaling, Wu, Xueping, Liu, Lei, Zhang, Haifeng, Yang, Lijuan, Chen, Weidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006764/ https://www.ncbi.nlm.nih.gov/pubmed/31957527 http://dx.doi.org/10.1080/0886022X.2020.1713806 |
Ejemplares similares
-
Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults
por: Wu, Xueping, et al.
Publicado: (2018) -
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial
por: Ni, Zhaohui, et al.
Publicado: (2021) -
Analysis of glomerular PLA2R efficacy in evaluating the prognosis of idiopathic membranous nephropathy in the background of different serum anti-PLA2R levels
por: Sun, Yuemeng, et al.
Publicado: (2022) -
The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy
por: Chen, Yang, et al.
Publicado: (2023) -
Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy
por: Shang, Shunlai, et al.
Publicado: (2022)